The Discounted Cash Flow (DCF) valuation of Jounce Therapeutics Inc (JNCE) is (23.41) USD. With the latest stock price at 1.88 USD, the upside of Jounce Therapeutics Inc based on DCF is -1345.3%.
Based on the latest price of 1.88 USD and our DCF valuation, Jounce Therapeutics Inc (JNCE) is a sell. selling JNCE stocks now will result in a potential gain of 1345.3%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 7.4% | 6.6% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (68.74) - (13.76) | (23.41) |
| Upside | -3756.2% - -831.9% | -1345.3% |